Objective: Ileal neobladders (INBs) are routinely created in patients following cystectomy for urothelial carcinoma (UC). Patients are screened by urinary cytology for tumor recurrence. However, the diagnosis of urothelial atypia remains a nonstandardized category in INB specimens and has never been studied before. Study Design: The cytopathology archives from the Johns Hopkins Hospital were searched over a period of 19 years for specimens from patients with INB and atypical urine cytology. Follow-up surgical pathology results and clinical data were reviewed. Results: A total of 620 urine specimens were identified from patients with INB, 77 of which (12.4%) were diagnosed as ‘atypical’. Of the 51 patients who were followed up, only 3 developed a concordant local recurrence (5.9% positive predictive value), defined as biopsy-proven recurrence within 1 year of atypical cytology. The recurrent patients had more diagnoses of ‘atypical cells suspicious for carcinoma’ than nonrecurrent patients (66 vs. 11.4%; p > 0.10). Conclusion: A diagnosis of urothelial atypia in patients with INB is made as frequently as in patients with native bladders but with a lower positive predictive value (5.9 vs. 12%) for subsequent histologic diagnosis of UC. This suggests that the diagnosis of urothelial atypia in INB may have less clinical significance than in native bladders.

Keywords:
Urine, Cytology, Bladder, Urothelial carcinoma
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.